Clinical Trial

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Name: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age — clinical trial record (NCT06113198)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republic of Korea according to a 2-dose primary schedule and 1 booster dose.

Trial Details

NCT Number	NCT06113198
Lead Sponsor	GlaxoSmithKline
Conditions	Meningitis, Meningococcal
Enrollment	50 participants
Start Date	2023-11-10
Primary Completion	2026-09-07 (estimated)
Study Completion	2027-02-08 (estimated)
Updated on ClinicalTrials.gov	2026-04-06